Treatment of syndrome of resistance to thyroid hormone beta: 2023 consensus statements from the Japan Thyroid Association

Sumiyasu Ishii , Kazumichi Onigata , Shigekazu Sasaki , Junta Takamatsu , Tetsuya Tagami , Kyoko Takeda , Matsuo Taniyama , Eijun Nishihara , Yoshitaka Hayashi , Akira Hishinuma , Shuji Fukata , Yoshiharu Murata , Masanobu Yamada
{"title":"Treatment of syndrome of resistance to thyroid hormone beta: 2023 consensus statements from the Japan Thyroid Association","authors":"Sumiyasu Ishii ,&nbsp;Kazumichi Onigata ,&nbsp;Shigekazu Sasaki ,&nbsp;Junta Takamatsu ,&nbsp;Tetsuya Tagami ,&nbsp;Kyoko Takeda ,&nbsp;Matsuo Taniyama ,&nbsp;Eijun Nishihara ,&nbsp;Yoshitaka Hayashi ,&nbsp;Akira Hishinuma ,&nbsp;Shuji Fukata ,&nbsp;Yoshiharu Murata ,&nbsp;Masanobu Yamada","doi":"10.1016/j.thscie.2025.100025","DOIUrl":null,"url":null,"abstract":"<div><div>Syndrome of resistance to thyroid hormone beta (RTHβ) is a familial syndrome of reduced responsiveness of target tissues to thyroid hormone, which is mainly induced by mutations in the <em>THRB</em> gene. The Japan Thyroid Association systematically reviewed literatures and published the consensus statements on the treatment of RTHβ in April 2023. RTHβ is sometimes inappropriately diagnosed with Graves’ disease because of high thyroid hormone levels, resulting in unnecessary treatment. In addition, there is a discrepancy between the estimated prevalence and the numbers of the reported cases, suggesting that many patients remain undiagnosed. Furthermore, it is not widely known how to treat this syndrome. Therefore, guidelines for the diagnosis and treatment of RTHβ are needed. We have established a diagnostic criteria and degree of severity for RTHβ in 2016. Here systematic review was done based on the GRADE approach. The statements include thirteen topics; four foreground clinical questions, five narrative background clinical questions, and four drugs that are not covered by health insurance in Japan. The recommendations and comments were prepared by the committee members, and the statements were further modified based on public comments. To our knowledge, this is the first consensus statements by a nation-wide academic society regarding the treatment of RTHβ based on a systematic review. This translated edition enables us to disclose Japanese consensus statements on the treatment of RTHβ to other countries and is expected to contribute to better treatment of RTHβ, but these statements should be referred in a realistic and flexible manner.</div></div>","PeriodicalId":101253,"journal":{"name":"Thyroid Science","volume":"2 2","pages":"Article 100025"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950300025000035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Syndrome of resistance to thyroid hormone beta (RTHβ) is a familial syndrome of reduced responsiveness of target tissues to thyroid hormone, which is mainly induced by mutations in the THRB gene. The Japan Thyroid Association systematically reviewed literatures and published the consensus statements on the treatment of RTHβ in April 2023. RTHβ is sometimes inappropriately diagnosed with Graves’ disease because of high thyroid hormone levels, resulting in unnecessary treatment. In addition, there is a discrepancy between the estimated prevalence and the numbers of the reported cases, suggesting that many patients remain undiagnosed. Furthermore, it is not widely known how to treat this syndrome. Therefore, guidelines for the diagnosis and treatment of RTHβ are needed. We have established a diagnostic criteria and degree of severity for RTHβ in 2016. Here systematic review was done based on the GRADE approach. The statements include thirteen topics; four foreground clinical questions, five narrative background clinical questions, and four drugs that are not covered by health insurance in Japan. The recommendations and comments were prepared by the committee members, and the statements were further modified based on public comments. To our knowledge, this is the first consensus statements by a nation-wide academic society regarding the treatment of RTHβ based on a systematic review. This translated edition enables us to disclose Japanese consensus statements on the treatment of RTHβ to other countries and is expected to contribute to better treatment of RTHβ, but these statements should be referred in a realistic and flexible manner.
甲状腺激素抵抗综合征的治疗:日本甲状腺协会2023年共识声明
甲状腺激素β抵抗综合征(RTHβ)是一种靶组织对甲状腺激素反应性降低的家族性综合征,主要由THRB基因突变诱发。日本甲状腺协会系统回顾了相关文献,并于2023年4月发布了关于RTHβ治疗的共识声明。由于甲状腺激素水平较高,RTHβ有时会被不恰当地诊断为巴塞杜氏病,从而导致不必要的治疗。此外,估计患病率与报告病例数之间存在差异,这表明许多患者仍未得到诊断。此外,人们对如何治疗这种综合征也不甚了解。因此,需要制定 RTHβ 的诊断和治疗指南。我们已于 2016 年制定了 RTHβ 的诊断标准和严重程度。在此,我们根据 GRADE 方法进行了系统回顾。陈述包括 13 个主题;4 个前景临床问题、5 个叙述性背景临床问题和 4 种日本医疗保险不覆盖的药物。建议和意见由委员会成员编写,并根据公众意见对声明作了进一步修改。据我们所知,这是第一份由全国性学术团体根据系统性回顾编写的有关 RTHβ 治疗的共识声明。本翻译版使我们能够向其他国家公开日本关于 RTHβ 治疗的共识声明,并有望为更好地治疗 RTHβ 做出贡献,但这些声明应以现实和灵活的方式进行参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信